Stock AGN ARGENICA THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Argenica Therapeutics Limited

Equities

AGN

AU0000150328

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 02:10:14 2024-05-09 EDT 		5-day change 1st Jan Change
0.615 AUD -4.65% Intraday chart for Argenica Therapeutics Limited +5.13% +20.59%
04-16 Euroz Hartleys Adjusts Argenica Therapeutics’ Price Target to AU$1.40 From AU$1.50, Keeps at Speculative Buy MT
04-12 Argenica Therapeutics Raises AU$12 Million via Placement MT

Valuation

Fiscal Period: Juni 2021 2022 2023
Capitalization 1 14.63 37.38 36.88
Enterprise Value (EV) 1 7.49 28.46 27.54
P/E ratio -6.88 x -7.77 x -6.82 x
Yield - - -
Capitalization / Revenue 49,428,185 x 144,256,486 x 21,076,392 x
EV / Revenue 25,298,505 x 109,850,751 x 15,739,424 x
EV / EBITDA - - -
EV / FCF -18,657,909 x -15,609,096 x -18,103,018 x
FCF Yield -0% -0% -0%
Price to Book 2.14 x 4.5 x 4.81 x
Nbr of stocks (in thousands) 73,172 86,922 98,351
Reference price 2 0.2000 0.4300 0.3750
Announcement Date 21-08-26 22-08-23 23-08-22
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Juni 2020 2021 2022 2023
Net sales - 0.2961 0.2591 1.75
EBITDA - - - -
EBIT 1 -0.6577 -1.03 -4.092 -4.875
Operating Margin - -347.76% -1,579.49% -278.59%
Earnings before Tax (EBT) 1 -0.6573 -1.029 -4.091 -4.815
Net income 1 -0.6573 -1.03 -4.091 -4.815
Net margin - -347.72% -1,578.84% -275.16%
EPS - -0.0291 -0.0553 -0.0550
Free Cash Flow - -0.4015 -1.823 -1.521
FCF margin - -135.59% -703.76% -86.94%
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 21-06-09 21-08-26 22-08-23 23-08-22
1AUD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: Juni 2020 2021 2022 2023
Net Debt 1 - - - -
Net Cash position 1 0.34 7.14 8.91 9.34
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - -0.4 -1.82 -1.52
ROE (net income / shareholders' equity) - -30% -54% -60.3%
ROA (Net income/ Total Assets) - -16.8% -31.4% -32.8%
Assets 1 - 6.119 13.05 14.68
Book Value Per Share 2 0 0.0900 0.1000 0.0800
Cash Flow per Share 2 0.0100 0.1000 0.1000 0.0900
Capex - - - -
Capex / Sales - - - -
Announcement Date 21-06-09 21-08-26 22-08-23 23-08-22
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ARGENICA THERAPEUTICS LIMITED Stock Argenica Therapeutics Limited
+20.59% 52.07M
MODERNA, INC. Stock Moderna, Inc.
+25.47% 46.71B
LONZA GROUP AG Stock Lonza Group AG
+48.83% 41.8B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.10% 41.52B
CELLTRION, INC. Stock Celltrion, Inc.
-3.42% 29.55B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.41% 25.78B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.58% 19.26B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.48% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.25% 12.08B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.45% 11.98B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. AGN Stock
  4. Financials Argenica Therapeutics Limited
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW